“we'll almost certainly will announce more before the end of this calendar year”
→ Read the source episode
See Further announces additional therapeutic programs beyond CF-012 and CF-033 by December 31, 2026
Jean Mack predicts Phase 2 will enroll patients across Australia, potentially Europe, and the United States
Deborah Research will identify and move the most promising read-through molecule candidates into first-in-human clinical studies.
Deborah Research is supporting development of a self-cooling sole for sneakers to address blister problems in EB patients.
Jean Mack predicts GAIN's IND will be cleared by the FDA within weeks and Phase 2 will begin in Q3 2026
Lu Gao predicts Therona will file INDs in parallel in the US and China in Q4 2026
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.